BOEHRINGER INGELHEIM EXTENDS RESEARCH COLLABORATION WITH ABLYNX FOR ALZHEIMER’S DISEASE

GHENT, BELGIUM–(EMWNews – August 21, 2008) –

GHENT, Belgium, 21 August 2008 – Ablynx [Euronext Brussels: ABLX], a

pioneer in the discovery and development of Nanobodies®, a novel

class of antibody-derived therapeutic proteins, announced today that

the Alzheimer’s disease collaboration with Boehringer Ingelheim was

proceeding well and therefore the research funding has been extended

for another year.

In January 2007 Boehringer Ingelheim and Ablynx announced that they

had entered into a $265 million worldwide research and licensing

agreement to discover and develop new therapies for Alzheimer’s

disease using Ablynx’s Nanobodies®, a novel class of therapeutic

proteins. The deal also included a joint research programme with

Ablynx scientists. Boehringer Ingelheim will be solely responsible

for the development, manufacture and commercialization of any

products resulting from the collaboration. As part of the

collaboration, Ablynx received an upfront fee and will receive

development and commercial milestones as well as undisclosed

royalties based on net sales.

Dr. Edwin Moses, CEO and Chairman of Ablynx, commented:

“We are very pleased with the progress that has been made in our

joint Alzheimer’s disease programme with Boehringer Ingelheim. We

look forward to continue working together with Boehringer Ingelheim

in this medical area which urgently requires an innovative approach.”

For more information, please contact:



College Hill Life Sciences - for UK/International media enquiries:

Sue Charles, Justine Lamond, John McIntyre

t:   +44 (0)20 7866 7857

f:   +44 (0)20 7866 7900

e:  [email protected]



Ablynx:

Dr Edwin Moses

Chairman and CEO

t:   +32 (0)9 262 00 07

m: +44 (0)7771 954 193 / +32 (0)473 39 50 68

e:  [email protected]



Eva-Lotta Allan

Chief Business Officer

t:   +32 (0)9 262 00 75

m: +32 (0)475 78 36 21 / +44 (0)7990 570 900

e:  [email protected]

Complete version of the press release in English —

http://hugin.info/137912/R/1245045/268654.pdf

Copyright © Hugin AS 2008. All rights reserved.